Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Bordag, Natalie ^a   Klie, Sebastian ^b   Jürchott, Kathrin ^c   Vierheller, Janine ^c   Schiewe, Hajo ^d   Albrecht, Valerie ^e   Tonn, Jörg Christian ^e   Schwartz, Christoph ^e   Schichor, Christian ^e   Selbig, Joachim ^c  

^a Metanomics GmbH   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PLANT PHYSIOLOGY   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d Metanomics Health GmbH   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; DEXAMETHASONE; GLUCOCORTICOID; PANTOPRAZOLE;

ADULT; CIRCADIAN RHYTHM; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; DEXAMETHASONE; GLUCOCORTICOIDS; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84946554429     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15954     Document Type: Article

References (74)

1. Van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. QJM 93, 105-11 (2000).
2. Sarnes, E. et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin. Ther. 33, 1413-32, doi: 10.1016/j.clinthera.2011.09.009 (2011).
3. Manson, S. C., Brown, R. E., Cerulli, A. & Vidaurre, C. F. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir. Med. 103, 975-994 (2009).
4. Hopkins, R. L. & Leinung, M. C. Exogenous Cushings syndrome and glucocorticoid withdrawal. Endocrinol. Metab. Clin. North Am. 34, 371-84, ix, doi: 10.1016/j.ecl.2005.01.013 (2005).
5. Geer, E. B., Islam, J. & Buettner, C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol. Metab. Clin. North Am. 43, 75-102, doi: 10.1016/j.ecl.2013.10.005 (2014).
6. Liu, D. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma. Clin. Immunol. 9, 30, doi: 10.1186/1710-1492-9-30 (2013).
7. Hougardy, D. M., Peterson, G. M., Bleasel, M. D. & Randall, C. T. Is enough attention being given to the adverse effects of corticosteroid therapy? J. Clin. Pharm. Ther. 25, 227-34 (2000).
8. Crokart, N. et al. Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin. Cancer Res. 13, 630-635, doi: 10.1158/1078-0432.CCR-06-0802 (2007).
9. N Chonghaile, T., Concannon, C. G., Szegezdi, E., Gorman, A. M. & Samali, A. Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Apoptosis 11, 1247-1255, doi: 10.1007/s10495-006-7233-1 (2006).
10. Uen, Y.-H. et al. Glucocorticoid protects hepatoma cells against metabolic stress-induced cell death. Int. J. Oncol. 33, 1263-1270, doi: 10.3892/ijo-00000117 (2008).
11. Weller, M., Schmidt, C., Roth, W. & Dichgans, J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48, 1704-1709, doi: 10.1212/WNL.48.6.1704 (1997).
12. Naumann, U., Durka, S. & Weller, M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/ CIP1 protein accumulation? Oncogene 17, 1567-75, doi: 10.1038/sj.onc.1202071 (1998).
13. Van Ravenzwaay, B. et al. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 172, 21-28, doi: 10.1016/j.toxlet.2007.05.021 (2007).
14. Walk, T. B. & Dostler, M. Mass spectrometry method for analyzing mixtures of substances. PCT/EP2003/001274, Patent WO2003073464 (2003).
15. Yamada, H. et al. Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine. J. Anal. Toxicol. 26, 17-22, doi: 10.1093/jat/26.1.17 (2002).
16. Mutch, D. M. et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One 4, e7905 (2009).
17. R Development Core Team, R. R: A language and environment for statistical computing. (2014).
18. Pinheiro, J., Bates, D., DebRoy, S. & Sarkar, D. Linear and nonlinear mixed effects models. R Packag. version 3, 57 (2007).
19. Plantes, H., lHermier des & Thiebaut, B. Etude de la pluviosite au moyen de la methode S.T.A.T.I.S. Rev. Stat. Appliquee 25, 57-81 (1977).
20. Lavit, C., Escoufier, Y., Sabatier, R. & Traissac, P. The ACT (STATIS method). Comput. Stat. Data Anal. 18, 97-119 (1994).
21. Dray, S. & Dufour, A.-B. The ade4 package: implementing the duality diagram for ecologists. J. Stat. Softw. 22, 1-20 (2007).
22. Dejea, S., Gonzalez, I. & With, K.-A. L. C. Omics data integration projec. R Packag. version 5.0, 3 (2012).
23. Klie, S. et al. Conserved changes in the dynamics of metabolic processes during fruit development and ripening across species. Plant Physiol. 164, 55-68, doi: 10.1104/pp.113.226142 (2014).
24. Sachs, G., Shin, J. M. & Hunt, R. Novel approaches to inhibition of gastric acid secretion. Curr. Gastroenterol. Rep. 12, 437-47, doi: 10.1007/s11894-010-0149-5 (2010).
25. Minami, Y. et al. Measurement of internal body time by blood metabolomics. Proc. Natl. Acad. Sci. USA. 106, 9890-9895, doi: 10.1073/pnas.0900617106 (2009).
26. Dallmann, R., Viola, A. U., Tarokh, L., Cajochen, C. & Brown, S. A. The human circadian metabolome. Proc. Natl. Acad. Sci. USA. 109, 2625-9, doi: 10.1073/pnas.1114410109 (2012).
27. Dickmeis, T. Glucocorticoids and the circadian clock. J. Endocrinol. 200, 3-22, doi: 10.1677/JOE-08-0415 (2009).
28. Gruden, K. et al. A crossomics study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One 7, e28761, doi: 10.1371/journal.pone.0028761 (2012).
29. Abdi, H., Williams, L. J., Valentin, D. & Bennani-Dosse, M. STATIS and DISTATIS: optimum multitable principal component analysis and three way metric multidimensional scaling. Wiley Interdiscip. Rev. Comput. Stat. 4, 124-167, doi: 10.1002/wics.198 (2012).
30. Meikle, A. W. & Tyler, F. H. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am. J. Med. 63, 200-7 (1977).
31. Andrews, M. H., Wood, S. A., Windle, R. J., Lightman, S. L. & Ingram, C. D. Acute glucocorticoid administration rapidly suppresses basal and stress-induced hypothalamo-pituitary-adrenal axis activity. Endocrinology 153, 200-11, doi: 10.1210/ en.2011-1434 (2012).
32. Parvez, H. & Parvez, S. Control of catecholamine release and degradation by the glucocorticoids. Experientia 28, 1330-2 (1972).
33. Bettini, V., Legrenzi, E., Mayellaro, F. & Zappetti, M. [Influence of dexamethasone on the responses of isolated coronary arteries to adrenaline]. Boll. Soc. Ital. Biol. Sper. 54, 2191-4 (1978).
34. Youdim, M. B., Banerjee, D. K., Kelner, K., Offutt, L. & Pollard, H. B. Steroid regulation of monoamine oxidase activity in the adrenal medulla. FASEB J. 3, 1753-9 (1989).
35. Arun, C. P. Fight or flight, forbearance and fortitude: the spectrum of actions of the catecholamines and their cousins. Ann. N. Y. Acad. Sci. 1018, 137-140, doi: 10.1196/annals.1296.016 (2004).
36. Szelenyi, J. & Vizi, E. S. The catecholamine cytokine balance: interaction between the brain and the immune system. Ann. N. Y. Acad. Sci. 1113, 311-324, doi: 10.1196/annals.1391.026 (2007).
37. Sumiyoshi, T. et al. Effect of mental stress on plasma homovanillic acid in healthy human subjects. Neuropsychopharmacology 19, 70-3, doi: 10.1016/S0893-133X(98)00005-0 (1998).
38. Wolkowitz, O. M. et al. Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Res. 16, 101-9 (1985).
39. Davila, R., Zumarraga, M., Basterreche, N., Arre, A. & Anguiano, J. B. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms. Psychiatry Res. 151, 163-8, doi: 10.1016/j.psychres.2005.07.039 (2007).
40. Judd, L. L. et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am. J. Psychiatry 171, 1045-51, doi: 10.1176/appi.ajp.2014.13091264 (2014).
41. Panin, L. E. & Usynin, I. F. Role of glucocorticoids and resident liver macrophages in induction of tyrosine aminotransferase. Biochemistry. (Mosc). 73, 305-309, doi: 10.1134/S0006297908030103 (2008).
42. Williams, L. R., Sandquist, D., Black, A. C. & Williams, T. H. Glucocorticoids increase tyrosine hydroxylase activity in cultured murine neuroblastoma. J. Neurochem. 36, 2057-2062 (1981).
43. Rass, I. T. Blood content of tyrosine is an index of glucocorticoid action on metabolism. Biochemistry. (Mosc). 75, 353-366, doi: 10.1134/S0006297910030120 (2010).
44. Chaouloff, F. Serotonin, stress and corticoids. J. Psychopharmacol. 14, 139-151, doi: 10.1177/026988110001400414 (2000).
45. Glatz, K., Mossner, R., Heils, A. & Lesch, K. P. Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. J. Neurochem. 86, 1072-1078, doi: 10.1046/j.1471-4159.2003.01944.x (2003).
46. Clark, J. A. et al. Glucocorticoid modulation of tryptophan hydroxylase-2 protein in raphe nuclei and 5-hydroxytryptophan concentrations in frontal cortex of C57/Bl6 mice. Mol. Psychiatry 13, 498-506, doi: 10.1038/sj.mp.4002041 (2008).
47. Padberg, I. et al. A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology. PLoS One 9, e85082, doi: 10.1371/journal.pone.0085082 (2014).
48. Poulos, A. Very long chain fatty acids in higher animals-a review. Lipids 30, 1-14, doi: 10.1007/BF02537036 (1995).
49. Serhan, C. N. & Petasis, N. A. Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-43, doi: 10.1021/ cr100396c (2011).
50. Kaur, G., Cameron-Smith, D., Garg, M. & Sinclair, A. J. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res. 50, 28-34, doi: 10.1016/j.plipres.2010.07.004 (2011).
51. Horrocks, L. A. & Yeo, Y. K. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 40, 211-25, doi: 10.1006/ phrs.1999.0495 (1999).
52. Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. Journal of Clinical Investigation 121, 4222-4230, doi: 10.1172/JCI57144 (2011).
53. Wu, D. et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J. Immunol. 179, 4829-39 (2007).
54. Yoo, J.-M. et al. Protection of LLC-PK1 cells against hydrogen peroxide-induced cell death by modulation of ceramide level. Arch. Pharm. Res. 28, 311-8 (2005).
55. Nieuwenhuis, B. et al. Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J. Mol. Med. (Berl). 87, 645-657, doi: 10.1007/ s00109-009-0468-x (2009).
56. Vasta, V. et al. Sphingosine 1-phosphate induces arachidonic acid mobilization in A549 human lung adenocarcinoma cells. Biochim. Biophys. Acta 1483, 154-160, doi: 10.1016/S1388-1981(99)00183-3 (2000).
57. Lamour, N. F. & Chalfant, C. E. Ceramide-1-phosphate: the missing link in eicosanoid biosynthesis and inflammation. Mol. Interv. 5, 358-367, doi: 10.1124/mi.5.6.8 (2005).
58. Schakman, O., Gilson, H. & Thissen, J. P. Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol. 197, 1-10, doi: 10.1677/JOE-07-0606 (2008).
59. Schakman, O., Gilson, H., Kalista, S. & Thissen, J. P. Mechanisms of muscle atrophy induced by glucocorticoids. Horm. Res. 72 Suppl 1, 36-41, doi: 10.1159/000229762 (2009).
60. Betheil, J. J., Feigelson, M. & Feigelson, P. The differential effects of glucocorticoid on tissue and plasma amino acid levels. Biochim. Biophys. Acta 104, 92-7 (1965).
61. Thorn, C. F., Lu, Z.-Y. & Whitehead, A. S. Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells. Eur. J. Immunol. 33, 2630-2639, doi: 10.1002/eji.200323985 (2003).
62. Liu, Q.-S., Nilsen-Hamilton, M. & Xiong, S.-D. Synergistic regulation of the acute phase protein SIP24/24p3 by glucocorticoid and pro-inflammatory cytokines. Sheng Li Xue Bao 55, 525-9 (2003).
63. Gross, V. et al. Induction of acute phase proteins by dexamethasone in rat hepatocyte primary cultures. Exp. Cell Res. 151, 46-54, doi: 10.1016/0014-4827(84)90354-9 (1984).
64. Mansoor, O. et al. Effect of an enteral diet supplemented with a specific blend of amino acid on plasma and muscle protein synthesis in ICU patients. Clin. Nutr. 26, 30-40, doi: 10.1016/j.clnu.2006.07.007 (2007).
65. Minisola, S., Antonelli, R. & Mazzuoli, G. Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease. J. Clin. Chem. Clin. Biochem. 23, 515-519, doi: 10.1515/cclm.1985.23.9.515 (1985).
66. Garnero, P. & Delmas, P. D. New developments in biochemical markers for osteoporosis. Calcif. Tissue Int. 59 Suppl 1, S2-S9, doi: 10.1007/s002239900168 (1996).
67. Hurson, C. J. et al. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet. Disord. 8, 12 (2007).
68. Rauch, A. et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517-531, doi: 10.1016/j.cmet.2010.05.005 (2010).
69. Gieger, C. et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 4, e1000282, doi: 10.1371/journal.pgen.1000282 (2008).
70. Assfalg, M. et al. Evidence of different metabolic phenotypes in humans. Proc. Natl. Acad. Sci. USA. 105, 1420-4, doi: 10.1073/ pnas.0705685105 (2008).
71. Bernini, P. et al. Individual human phenotypes in metabolic space and time. J. Proteome Res. 8, 4264-71, doi: 10.1021/pr900344m (2009).
72. Heinzmann, S. S. et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. J. Proteome Res. 11, 643-55, doi: 10.1021/pr2005764 (2012).
73. Debono, M. & Ross, R. J. Optimal glucocorticoid therapy. Endocr. Dev. 20, 173-180, doi: 10.1159/000321241 (2011).
74. Bagher, O. M., Golbarg, M. & Mosadegh Moneyreh, M. Bedtime single-dose prednisolone in clinically stable rheumatoid arthritis patients. ISRN Pharmacology 2012, 1-5, doi: 10.5402/2012/637204 (2012).